Meeting Banner
Abstract #0509

Does ADC better predict tumour cellularity or necrosis?  A multi-centre multi-vendor study in twelve rodent tumour models

John C Waterton1, Dominick McIntyre2, François-Xavier Blé3, Sabrina Doblas4, Eric Aboagye5, Kathrin Heinzmann2, Sandra Heskamp6, James PB O'Connor1, Sonja Schelhaas7, Lydia Wachsmuth8, Hervé Barjat9, Cara Brodie2, Dominique-Laurent Couturier2, Cornelius Faber8, Heather Flynn10, Philippe Garteiser4, Andreas Jacobs7, Bernard Van Beers4, Kaye Williams1, and Davina Honess2

1University of Manchester, Manchester, United Kingdom, 2Cancer Research UK Cambridge Institute, Cambridge, United Kingdom, 3AstraZeneca, Cambridge, United Kingdom, 4INSERM Center for Research on Inflammation, Paris, France, 5Imperial College, London, United Kingdom, 6Radboud University Medical Center, Nijmegen, Netherlands, 7European Institute for Molecular Imaging, University of Münster, Münster, Germany, 8TRIC, University Hospital, University of Münster, Münster, Germany, 9STFC, Daresbury, United Kingdom, 10Bioxydyn, Manchester, United Kingdom

We studied tumour Apparent Diffusion Coefficient (ADC), necrosis and cellularity in untreated rodent tumours of twelve types from six centres using two different vendors’ equipment. Tumour types included human xenografts (conventional and patient-derived) genetically engineered mouse tumours and syngeneic rat tumours. Across this broad spectrum there was a robust inverse correlation between ADC and cellularity, and a weaker positive correlation between ADC and necrosis. ADC mean and median were the best correlates for cellularity, while ADC standard deviation and kurtosis provided the best correlates for necrosis. This work advances the biological validation of ADC as a biomarker of tumour cellularity.

This abstract and the presentation materials are available to members only; a login is required.

Join Here